Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Synthesis of Spin-Labelled Bergamottin: A Potent CYP3A4 Inhibitor with Antiproliferative Activity.

Zsidó BZ, Balog M, Erős N, Poór M, Mohos V, Fliszár-Nyúl E, Hetényi C, Nagane M, Hideg K, Kálai T, Bognár B.

Int J Mol Sci. 2020 Jan 13;21(2). pii: E508. doi: 10.3390/ijms21020508.

2.

Diarylidenylpiperidones, H-4073 and HO-3867, Induce G2/M Cell-Cycle Arrest, Apoptosis and Inhibit STAT3 Phosphorylation in Human Pancreatic Cancer Cells.

Mast JM, Tse D, Shee K, Lakshmi Kuppusamy M, Kmiec MM, Kálai T, Kuppusamy P.

Cell Biochem Biophys. 2019 Jun;77(2):109-119. doi: 10.1007/s12013-019-00873-6. Epub 2019 May 14.

PMID:
31089934
3.

Antiproliferative Effect of a Novel 4,4'-Disulfonyldiarylidenyl Piperidone in Human Colon Cancer Cells.

Prabhat AM, Kuppusamy ML, Bognár B, Kálai T, Hideg K, Kuppusamy P.

Cell Biochem Biophys. 2019 Mar;77(1):61-67. doi: 10.1007/s12013-018-0862-5. Epub 2018 Dec 14.

PMID:
30552554
4.

Oligomerization Alters Binding Affinity Between Amyloid Beta and a Modulator of Peptide Aggregation.

Hilt S, Rojalin T, Viitala T, Koivuniemi A, Bunker A, Hogiu SW, Kálai T, Hideg K, Yliperttula M, Voss JC.

J Phys Chem C Nanomater Interfaces. 2017 Nov 2;121(43):23974-23987. doi: 10.1021/acs.jpcc.7b06164. Epub 2017 Oct 10.

5.

A Bifunctional Anti-Amyloid Blocks Oxidative Stress and the Accumulation of Intraneuronal Amyloid-Beta.

Hilt S, Altman R, Kálai T, Maezawa I, Gong Q, Wachsmann-Hogiu S, Jin LW, Voss JC.

Molecules. 2018 Aug 12;23(8). pii: E2010. doi: 10.3390/molecules23082010.

6.

Synthesis and Biological Evaluation of Curcumin-Nitroxide-Based Molecular Hybrids as Antioxidant and Anti-Proliferative Agents.

Bognar B, Kuppusamy ML, Madan E, Kalai T, Balog M, Jeko J, Kuppusamy P, Hideg K.

Med Chem. 2017;13(8):761-772. doi: 10.2174/1871520617666170522124712.

PMID:
28530545
7.

Chronic PARP-1 inhibition reduces carotid vessel remodeling and oxidative damage of the dorsal hippocampus in spontaneously hypertensive rats.

Eros K, Magyar K, Deres L, Skazel A, Riba A, Vamos Z, Kalai T, Gallyas F Jr, Sumegi B, Toth K, Halmosi R.

PLoS One. 2017 Mar 24;12(3):e0174401. doi: 10.1371/journal.pone.0174401. eCollection 2017.

8.

A Metal-Free Method for Producing MRI Contrast at Amyloid-β.

Hilt S, Tang T, Walton JH, Budamagunta M, Maezawa I, Kálai T, Hideg K, Singh V, Wulff H, Gong Q, Jin LW, Louie A, Voss JC.

J Alzheimers Dis. 2017;55(4):1667-1681. doi: 10.3233/JAD-160279.

9.

Protective spin-labeled fluorenes maintain amyloid beta peptide in small oligomers and limit transitions in secondary structure.

Altman R, Ly S, Hilt S, Petrlova J, Maezawa I, Kálai T, Hideg K, Jin LW, Laurence TA, Voss JC.

Biochim Biophys Acta. 2015 Dec;1854(12):1860-1870. doi: 10.1016/j.bbapap.2015.09.002. Epub 2015 Sep 14.

10.

Differential response of NADP-dehydrogenases and carbon metabolism in leaves and roots of two durum wheat (Triticum durum Desf.) cultivars (Karim and Azizi) with different sensitivities to salt stress.

Bouthour D, Kalai T, Chaffei HC, Gouia H, Corpas FJ.

J Plant Physiol. 2015 May 1;179:56-63. doi: 10.1016/j.jplph.2015.02.009. Epub 2015 Mar 18.

PMID:
25835711
11.

PARP-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1/GSK-3β and several PKC isoforms.

Deres L, Bartha E, Palfi A, Eros K, Riba A, Lantos J, Kalai T, Hideg K, Sumegi B, Gallyas F, Toth K, Halmosi R.

PLoS One. 2014 Jul 11;9(7):e102148. doi: 10.1371/journal.pone.0102148. eCollection 2014.

12.

PARP inhibitor attenuated colony formation can be restored by MAP kinase inhibitors in different irradiated cancer cell lines.

Hocsak E, Cseh A, Szabo A, Bellyei S, Pozsgai E, Kalai T, Hideg K, Sumegi B, Boronkai A.

Int J Radiat Biol. 2014 Dec;90(12):1152-61. doi: 10.3109/09553002.2014.934927. Epub 2014 Nov 14.

PMID:
24937370
13.

Synthesis and functional survey of new Tacrine analogs modified with nitroxides or their precursors.

Kálai T, Altman R, Maezawa I, Balog M, Morisseau C, Petrlova J, Hammock BD, Jin LW, Trudell JR, Voss JC, Hideg K.

Eur J Med Chem. 2014 Apr 22;77:343-50. doi: 10.1016/j.ejmech.2014.03.026. Epub 2014 Mar 12.

14.

Assessing the Applicability of Singlet Oxygen Photosensitizers in Leaf Studies.

Kovács L, Ayaydin F, Kálai T, Tandori J, Kós PB, Hideg É.

Photochem Photobiol. 2014 Jan;90(1):129-36. doi: 10.1111/php.12148. Epub 2013 Sep 4.

PMID:
23927573
15.

Pulmonary hypertension secondary to left-heart failure involves peroxynitrite-induced downregulation of PTEN in the lung.

Ravi Y, Selvendiran K, Naidu SK, Meduru S, Citro LA, Bognár B, Khan M, Kálai T, Hideg K, Kuppusamy P, Sai-Sudhakar CB.

Hypertension. 2013 Mar;61(3):593-601. doi: 10.1161/HYPERTENSIONAHA.111.00514. Epub 2013 Jan 21.

16.

Synthesis and potential use of 1,8-naphthalimide type (1)O2 sensor molecules.

Kálai T, Hideg É, Ayaydin F, Hideg K.

Photochem Photobiol Sci. 2013 Mar;12(3):432-8. doi: 10.1039/c2pp25253h.

PMID:
23160310
17.

The influence of spin-labeled fluorene compounds on the assembly and toxicity of the aβ peptide.

Petrlova J, Kálai T, Maezawa I, Altman R, Harishchandra G, Hong HS, Bricarello DA, Parikh AN, Lorigan GA, Jin LW, Hideg K, Voss JC.

PLoS One. 2012;7(4):e35443. doi: 10.1371/journal.pone.0035443. Epub 2012 Apr 30.

18.

Synthesis and study of new paramagnetic resveratrol analogues.

Kálai T, Borza E, Antus C, Radnai B, Gulyás-Fekete G, Fehér A, Sümegi B, Hideg K.

Bioorg Med Chem. 2011 Dec 15;19(24):7311-7. doi: 10.1016/j.bmc.2011.10.066. Epub 2011 Oct 28.

PMID:
22088309
19.

A rigid disulfide-linked nitroxide side chain simplifies the quantitative analysis of PRE data.

Fawzi NL, Fleissner MR, Anthis NJ, Kálai T, Hideg K, Hubbell WL, Clore GM.

J Biomol NMR. 2011 Sep;51(1-2):105-14. doi: 10.1007/s10858-011-9545-x. Epub 2011 Sep 27.

20.

Structure and dynamics of a conformationally constrained nitroxide side chain and applications in EPR spectroscopy.

Fleissner MR, Bridges MD, Brooks EK, Cascio D, Kálai T, Hideg K, Hubbell WL.

Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16241-6. doi: 10.1073/pnas.1111420108. Epub 2011 Sep 12.

21.

HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.

Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

Cancer Biol Ther. 2011 Nov 1;12(9):837-45. doi: 10.4161/cbt.12.9.17713. Epub 2011 Nov 1.

PMID:
21885917
22.

Amelioration of doxorubicin-induced cardiotoxicity by an anticancer-antioxidant dual-function compound, HO-3867.

Dayton A, Selvendiran K, Meduru S, Khan M, Kuppusamy ML, Naidu S, Kálai T, Hideg K, Kuppusamy P.

J Pharmacol Exp Ther. 2011 Nov;339(2):350-7. doi: 10.1124/jpet.111.183681. Epub 2011 Jul 28.

23.

Synthesis of N-substituted 3,5-bis(arylidene)-4-piperidones with high antitumor and antioxidant activity.

Kálai T, Kuppusamy ML, Balog M, Selvendiran K, Rivera BK, Kuppusamy P, Hideg K.

J Med Chem. 2011 Aug 11;54(15):5414-21. doi: 10.1021/jm200353f. Epub 2011 Jul 6.

PMID:
21702507
24.

Dynamics of tropomyosin in muscle fibers as monitored by saturation transfer EPR of bi-functional probe.

Rayes RF, Kálai T, Hideg K, Geeves MA, Fajer PG.

PLoS One. 2011;6(6):e21277. doi: 10.1371/journal.pone.0021277. Epub 2011 Jun 20.

25.

Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure.

Bartha E, Solti I, Szabo A, Olah G, Magyar K, Szabados E, Kalai T, Hideg K, Toth K, Gero D, Szabo C, Sumegi B, Halmosi R.

J Cardiovasc Pharmacol. 2011 Oct;58(4):380-91. doi: 10.1097/FJC.0b013e318225c21e.

PMID:
21697725
26.

Synthesis and study of 2-amino-7-bromofluorenes modified with nitroxides and their precursors as dual anti-amyloid and antioxidant active compounds.

Kálai T, Petrlova J, Balog M, Aung HH, Voss JC, Hideg K.

Eur J Med Chem. 2011 Apr;46(4):1348-55. doi: 10.1016/j.ejmech.2011.01.059. Epub 2011 Feb 3.

27.

Induction of mitochondrial destabilization and necrotic cell death by apolar mitochondria-directed SOD mimetics.

Szabo A, Balog M, Mark L, Montsko G, Turi Z, Gallyas F Jr, Sumegi B, Kalai T, Hideg K, Kovacs K.

Mitochondrion. 2011 May;11(3):476-87. doi: 10.1016/j.mito.2011.01.006. Epub 2011 Feb 1.

PMID:
21292036
28.

Direct detection of free radicals and reactive oxygen species in thylakoids.

Hideg E, Kálai T, Hideg K.

Methods Mol Biol. 2011;684:187-200. doi: 10.1007/978-1-60761-925-3_16.

PMID:
20960131
29.

Cellular uptake, retention and bioabsorption of HO-3867, a fluorinated curcumin analog with potential antitumor properties.

Dayton A, Selvendiran K, Kuppusamy ML, Rivera BK, Meduru S, Kálai T, Hideg K, Kuppusamy P.

Cancer Biol Ther. 2010 Nov 15;10(10):1027-32. doi: 10.4161/cbt.10.10.13250. Epub 2010 Nov 15.

30.

HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase.

Selvendiran K, Ahmed S, Dayton A, Ravi Y, Kuppusamy ML, Bratasz A, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

Mol Cancer Res. 2010 Sep;8(9):1188-97. doi: 10.1158/1541-7786.MCR-10-0201. Epub 2010 Aug 16.

31.

Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts.

Selvendiran K, Tong L, Bratasz A, Kuppusamy ML, Ahmed S, Ravi Y, Trigg NJ, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

Mol Cancer Ther. 2010 May;9(5):1169-79. doi: 10.1158/1535-7163.MCT-09-1207. Epub 2010 May 4.

32.

Synthesis and study of new paramagnetic and diamagnetic verapamil derivatives.

Bognár B, Ahmed S, Kuppusamy ML, Selvendiran K, Khan M, Jeko J, Hankovszky OH, Kálai T, Kuppusamy P, Hideg K.

Bioorg Med Chem. 2010 Apr 15;18(8):2954-63. doi: 10.1016/j.bmc.2010.02.040. Epub 2010 Feb 25.

33.

Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: differential cytotoxicity in healthy and cancer cells.

Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Tazi M, Bratasz A, Tong L, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

Free Radic Biol Med. 2010 May 1;48(9):1228-35. doi: 10.1016/j.freeradbiomed.2010.02.009. Epub 2010 Feb 12.

34.

Site-directed spin labeling of a genetically encoded unnatural amino acid.

Fleissner MR, Brustad EM, Kálai T, Altenbach C, Cascio D, Peters FB, Hideg K, Peuker S, Schultz PG, Hubbell WL.

Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21637-42. doi: 10.1073/pnas.0912009106. Epub 2009 Dec 7. Erratum in: Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5693. Peuker, Sebastian [added].

35.

VLDL lipolysis products increase VLDL fluidity and convert apolipoprotein E4 into a more expanded conformation.

Tetali SD, Budamagunta MS, Simion C, den Hartigh LJ, Kálai T, Hideg K, Hatters DM, Weisgraber KH, Voss JC, Rutledge JC.

J Lipid Res. 2010 Jun;51(6):1273-83. doi: 10.1194/jlr.M000406. Epub 2009 Dec 3.

36.

Site-specific DNA structural and dynamic features revealed by nucleotide-independent nitroxide probes.

Popova AM, Kálai T, Hideg K, Qin PZ.

Biochemistry. 2009 Sep 15;48(36):8540-50. doi: 10.1021/bi900860w.

37.

PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats.

Bartha E, Solti I, Kereskai L, Lantos J, Plozer E, Magyar K, Szabados E, Kálai T, Hideg K, Halmosi R, Sumegi B, Toth K.

Cardiovasc Res. 2009 Aug 1;83(3):501-10. doi: 10.1093/cvr/cvp144. Epub 2009 May 14.

PMID:
19443425
38.

Inhibition of vascular smooth-muscle cell proliferation and arterial restenosis by HO-3867, a novel synthetic curcuminoid, through up-regulation of PTEN expression.

Selvendiran K, Kuppusamy ML, Bratasz A, Tong L, Rivera BK, Rink C, Sen CK, Kálai T, Hideg K, Kuppusamy P.

J Pharmacol Exp Ther. 2009 Jun;329(3):959-66. doi: 10.1124/jpet.108.150367. Epub 2009 Mar 10.

PMID:
19276401
39.

New poly(ADP-ribose) polymerase-1 inhibitors with antioxidant activity based on 4-carboxamidobenzimidazole-2-ylpyrroline and -tetrahydropyridine nitroxides and their precursors.

Kálai T, Balog M, Szabó A, Gulyás G, Jeko J, Sümegi B, Hideg K.

J Med Chem. 2009 Mar 26;52(6):1619-29. doi: 10.1021/jm801476y.

PMID:
19245212
40.

Cardioprotection by HO-4038, a novel verapamil derivative, targeted against ischemia and reperfusion-mediated acute myocardial infarction.

Mohan IK, Khan M, Wisel S, Selvendiran K, Sridhar A, Carnes CA, Bognar B, Kálai T, Hideg K, Kuppusamy P.

Am J Physiol Heart Circ Physiol. 2009 Jan;296(1):H140-51. doi: 10.1152/ajpheart.00687.2008. Epub 2008 Oct 31.

41.

Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure.

Bartha E, Kiss GN, Kalman E, Kulcsár G, Kálai T, Hideg K, Habon T, Sumegi B, Toth K, Halmosi R.

J Cardiovasc Pharmacol. 2008 Sep;52(3):253-61. doi: 10.1097/FJC.0b013e3181855cef.

PMID:
18806606
42.

Novel antioxidants in anthracycline cardiotoxicity.

Hideg K, Kálai T.

Cardiovasc Toxicol. 2007;7(2):160-4. Review.

PMID:
17652823
43.

N-hydroxy-pyrroline modification of verapamil exhibits antioxidant protection of the heart against ischemia/reperfusion-induced cardiac dysfunction without compromising its calcium antagonistic activity.

Mandal R, Kutala VK, Khan M, Mohan IK, Varadharaj S, Sridhar A, Carnes CA, Kálai T, Hideg K, Kuppusamy P.

J Pharmacol Exp Ther. 2007 Oct;323(1):119-27. Epub 2007 Jul 23.

PMID:
17646427
44.
45.

A novel SOD-mimetic permeability transition inhibitor agent protects ischemic heart by inhibiting both apoptotic and necrotic cell death.

Bognar Z, Kalai T, Palfi A, Hanto K, Bognar B, Mark L, Szabo Z, Tapodi A, Radnai B, Sarszegi Z, Szanto A, Gallyas F Jr, Hideg K, Sumegi B, Varbiro G.

Free Radic Biol Med. 2006 Sep 1;41(5):835-48. Epub 2006 Jun 15.

PMID:
16895804
46.

Structural features of transiently modified beta-lactoglobulin relevant to the stable binding of large hydrophobic molecules.

Lozinsky E, Iametti S, Barbiroli A, Likhtenshtein GI, Kálai T, Hideg K, Bonomi F.

Protein J. 2006 Jan;25(1):1-15.

PMID:
16721656
47.

PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.

Palfi A, Toth A, Hanto K, Deres P, Szabados E, Szereday Z, Kulcsar G, Kalai T, Hideg K, Gallyas F Jr, Sumegi B, Toth K, Halmosi R.

J Mol Cell Cardiol. 2006 Jul;41(1):149-59. Epub 2006 May 23.

PMID:
16716347
48.

Structure-activity studies on the protection of Trimetazidine derivatives modified with nitroxides and their precursors from myocardial ischemia-reperfusion injury.

Kálai T, Khan M, Balog M, Kutala VK, Kuppusamy P, Hideg K.

Bioorg Med Chem. 2006 Aug 15;14(16):5510-6. Epub 2006 May 12.

PMID:
16697647
49.

Singlet oxygen in plants--its significance and possible detection with double (fluorescent and spin) indicator reagents.

Hideg E, Kálai T, Kós PB, Asada K, Hideg K.

Photochem Photobiol. 2006 Sep-Oct;82(5):1211-8.

PMID:
16608386
50.

Equilibrium and NMR studies on GdIII, YIII, CuII and ZnII complexes of various DTPA-N,N''-bis(amide) ligands. Kinetic stabilities of the gadolinium(III) complexes.

Jászberényi Z, Bányai I, Brücher E, Király R, Hideg K, Kálai T.

Dalton Trans. 2006 Feb 28;(8):1082-91. Epub 2005 Nov 24.

PMID:
16474894

Supplemental Content

Support Center